AstraZeneca vaccine turns dangerous in Pakistan, security related department bans use

DRAP allowed AstraZeneca Vaccine import when its use was banned in Europe . google image

ISLAMABAD: AstraZeneca C ovid-19 vaccine has proven dangerous for Pakistan as its receivers have developed serious side effects like fever, bleeding and chills that can be a risk to lives of the recipients.

Sources said AstraZeneca Covid-19 vaccine already banned by European Commission was being administrated by different private hospitals and laboratories in Pakistan.
EC has banned AstraZeneca vaccine as its use had caused some dangerous side effects. Particularly, its use in youth had resulted in blood clotting.

Despite ban by EC, DRAP allowed import of AstraZeneca vaccine and its being administrated in Pakistan by ignoring its serious side effects.

DRAP has approved the use of AstraZeneca vaccine in Pakistan . The DRAP Ignored EC ban on use of AstraZeneca vaccine and approved its use for preventing Pakistanis from Covid-19 infection.

Despite having reports of serious side effects of AstraZeneca vaccine, DRAP waiting of use of entire imported stock of AstraZeneca vaccine in Pakistan.

DRAP officials confirmed to NEWSMAN when approached for comments on Thursday that the authority has received some reports of side effects of AstraZeneca vaccine, but its not banning its use so far. He, however, disclosed that DRAP is not going to allow import and use of more AstraZeneca vaccine.

“We have reports of side effects of AstraZeneca vaccine but its use in Pakistan has not been banned so far”, DRAP official disclosed to NEWSMAN on the condition of anonymity.

The official, however, claimed that DRAP is not going to allow further import of AstraZeneca vaccine for use in Pakistan.

In a major development, some important security related institutions have banned its use for its personnel. One of the security departments has issued an advisory to all its concerned sections not to use AstraZeneca vaccine to prevent spread of CoVID- 19 pandemic.

Comments (0)
Add Comment